Rezolute, Inc. (RZLT) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US76200L3096
Rezolute, Inc. financials
| Fiscal year | 2025 | 2026 |
|---|---|---|
| Operating income | -79.89 m USD | -82.97 m USD |
| EBIT | -74.41 m USD | -77.59 m USD |
| Net income | -74.41 m USD | -77.59 m USD |
| Diluted EPS – continuing operations | -0.98 USD | -0.75 USD |
Full history since 2010, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
More stocks
- Austriacard Holdings AG (ACAG.AT)
- TPIsoftware (7781.TWO)
- Cerence Inc. (CRNC)
- Borussia Dortmund GmbH & Co. Kommanditgesellschaft auf Aktien (BVB.PR)
- Intellian Technologies Inc (189300.KQ)
- Leaguer Shenzhen MicroElectronics Corp (688589.SS)
- RF Materials Co. Ltd (327260.KQ)
- Yarward Electronics Shandong Co. Ltd. A (301337.SZ)
- Shen Zhen Australis Electronic Technology Co.Ltd. (300940.SZ)
- Goldkey Technology Corporation (3135.TW)
- Hangzhou Huaxing Chuangye Communication Technology Co Ltd (300025.SZ)
- Anhui Xinbo Aluminum Co Ltd (003038.SZ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.